Cellular Biomedicine Group, Inc. CBMG
No live quote for CBMG yet.
Analyst view
Consensus: hold
Hold
Price target (mean) 19.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
- 2 months ago 1
- 3 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.63 | 0.0% | 500.00K | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.82 | 0.0% | 500.00K | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 2.00M | +488.2% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 4.00M | +100.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 12, 2020 | Baird | Downgrade | Outperform | Neutral |
| Jul 12, 2020 | Baird | Upgrade | Neutral | Outperform |
| Mar 4, 2020 | BTIG Research | Downgrade | Buy | Neutral |
| Nov 11, 2019 | Baird | Downgrade | Outperform | Neutral |
| Sep 16, 2019 | BTIG | Initiated | — | Buy |
| Jun 24, 2019 | Cantor Fitzgerald | Initiated | — | Overweight |
| Feb 6, 2019 | Baird | Initiated | — | Outperform |
| Oct 2, 2018 | B. Riley FBR | Maintained | Buy | Buy |
| Sep 21, 2016 | Maxim Group | Initiated | — | Buy |